Home » Newsletters » BioWorld Science

BioWorld Science

March 17, 2006

View Archived Issues

Aliskiren displays dose-dependent antihypertensive effects

Intravenous and oral conivaptan raises serum sodium in heart failure patients

Studies compare AZD-6140 and clopidogrel in acute coronary syndromes

Darusentan demonstrates promise in resistant hypertension

Indacaterol well tolerated in mild and persistent asthma

Intravenous and subcutaneous immunoglobulin compared in immune deficiency

UCB signs research license agreement for Crucell's PER.C6 cell line

Viragen raises funds through private placement unit offering

Aeolus receives milestone and equity consideration from ARCA Discovery

CamBP collaborates with BTG

Treatment suspended in phase IIb GENASIS study

TGF-beta1 gene-silencing treatment for progressive renal diseases

Novel ACAT inhibitor SMP-797 enhances hepatic LDL receptor expression

DDP-225 begins phase II testing for chronic functional vomiting

Exosomes show potential in treatment of rheumatoid arthritis

Pivotal study of depsipeptide in CTCL expanded to U.S. sites

PharmAthene and SIGA Technologies announce plans to merge

BioDelivery Sciences International profiles pipeline

IND approval for phase I study of anticancer therapeutic IT-101

Xechem seeks orphan drug designation for antisickling agent 5-HMF

GeoVax cleared for clinical trials of HIV/AIDS vaccines

Stability issues close phase II trial of CTI-01

GlaxoSmithKline to begin Japanese study of cervical cancer vaccine

Donepezil improves measures of cognition in vascular dementia

Phenoptin reduces blood phenylalanine levels in PKU study

Chrysalin fails to meet primary efficacy endpoint in fracture repair study

Recent patents describe new treatments for endocrine-related disorders

Novel treatment options for metabolic disorders described in recent patents

European approval for Exelon in Parkinson's related dementia

FDA approval for Yaz

Preclinical data on CHR-2797, an aminopeptidase inhibitor in early clinical testing